OS Therapies Completes Private Placement with Gross Proceeds of $7.1 Million

On January 14, 2025, OS Therapies Incorporated (NYSE: OSTX), a company specializing in ADC and immunotherapy research and clinical-stage biopharmaceuticals, concluded a second closing of its private placement. The private placement had been initially revealed in the Company’s Form 8-K filed with the Securities and Exchange Commission on December 30, 2024, and further discussed in a subsequent filing on January 3, 2025.

The aggregate gross proceeds generated by OS Therapies from both the first and second closings of the private placement amount to approximately $7,103,000, before the subtraction of transaction fees and additional estimated expenses related to the private placement.

Following the second closing, the Board of Directors at OS Therapies has confirmed that no further closings will take place, signifying the completion of the private placement process.

In a statement included in the filing on January 14, 2025, the company’s President and Chief Executive Officer, Paul A. Romness, MPH, acknowledged the successful completion of the private placement.

The filing also indicated that as per Item 9.01, there will be the submission of financial statements and an exhibit (Exhibit 104 – Cover Page Interactive Data File embedded within the Inline XBRL document).

Through this development, OS Therapies stands to further its research and advancements in the ADC and immunotherapy space with the acquired funds from the private placement.

For more information and detailed financial statements, interested parties can refer to the official filing submitted to the Securities and Exchange Commission.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read OS Therapies’s 8K filing here.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.